Janus kinase 1. Every medicine in our data that ChEMBL or the Guide to Pharmacology records as acting on this protein, with the source for each and its current clinical trials on this site.
| Medicine | How it acts | Source | Current trials here |
|---|---|---|---|
| Ruxolitinib CHEMBL1789941 |
Tyrosine-protein kinase JAK1 inhibitor Inhibitor Small molecule |
✓ Both | 73 |
| Upadacitinib CHEMBL3622821 |
Tyrosine-protein kinase JAK1 inhibitor Inhibitor Small molecule |
✓ Both | 43 |
| Tofacitinib CHEMBL221959 |
Janus Kinase (JAK) inhibitor Inhibitor Small molecule |
✓ Both | 34 |
| Baricitinib CHEMBL2105759 |
Tyrosine-protein kinase JAK1 inhibitor Inhibitor Small molecule |
✓ Both | 31 |
| Golidocitinib CHEMBL4577523 |
Tyrosine-protein kinase JAK1 inhibitor Inhibitor Small molecule |
✓ Both | 21 |
| Abrocitinib CHEMBL3655081 |
Tyrosine-protein kinase JAK1 inhibitor Inhibitor Small molecule |
✓ Both | 11 |
| Filgotinib CHEMBL3301607 |
Tyrosine-protein kinase JAK1 inhibitor Inhibitor Small molecule |
✓ Both | 11 |
| Momelotinib CHEMBL1078178 |
Tyrosine-protein kinase JAK1 inhibitor Inhibitor Small molecule |
✓ Both | 5 |
| Delgocitinib CHEMBL4297507 |
Janus Kinase (JAK) inhibitor Inhibitor Small molecule |
✓ Both | 4 |
| Brepocitinib CHEMBL4297477 |
Tyrosine-protein kinase JAK1 inhibitor Inhibitor Small molecule |
✓ Both | 2 |
| Deuruxolitinib CHEMBL4594381 |
Inhibits JAK1 Primary target Small molecule |
Guide to Pharmacology only | 2 |
| Itacitinib CHEMBL3622820 |
Tyrosine-protein kinase JAK1 inhibitor Inhibitor Small molecule |
✓ Both | 2 |
“Both” means ChEMBL and the Guide to Pharmacology each record this medicine acting on this protein; “only” means one source records it and the other does not (often because it lists fewer secondary targets). The Guide to Pharmacology adds a medicine here only when this protein is its primary target. Medicines without a link have no page on this site yet.
| Disease | Medicines tested | Furthest trial phase |
|---|---|---|
| Alopecia areata | 7 | Phase 3 |
| Psoriasis | 5 | Phase 3 |
| Systemic lupus erythematosus | 4 | Phase 3 |
| COVID-19 | 3 | Phase 3 |
| Acute respiratory distress syndrome | 3 | Phase 3 |
| Hand eczema | 3 | Phase 3 |
| Hidradenitis suppurativa | 3 | Phase 3 |
| Primary myelofibrosis | 3 | Phase 3 |
| Ulcerative colitis | 3 | Phase 3 |
| Lichen planopilaris | 3 | Phase 2/3 |
| Asthma | 3 | Phase 2 |
| Non-small cell lung carcinoma | 3 | Phase 2 |
| Cognitive impairment | 2 | Phase 3 |
| Crohn disease | 2 | Phase 3 |
| Dyspnea | 2 | Phase 3 |
From ChEMBL's drug-disease records, which draw on trial registries. A trial phase is not an approval; approved uses are on each medicine's page from the regulators' own records.
Which medicines act on this protein comes from two independent, expert-curated sources: ChEMBL's mechanism-of-action records (via the Open Targets Platform) and the IUPHAR/BPS Guide to PHARMACOLOGY. Each row says which of them lists it. Data from them is shared here under their share-alike licences (CC BY-SA 3.0 and 4.0).
A job re-reads both sources every 30 days. Medicines are matched to our pages by exact name or a ChEMBL-curated synonym, and to the Guide to Pharmacology by ChEMBL ID or exact name, never by a close spelling. No AI drafting. See our methodology. The Open Targets data on this page was last retrieved on 30 Sep 2026. How every register is built: methodology · fixes we have made: corrections log.
